Results of a Phase III study showed that Human Genome Sciences Inc.'s Albuferon (albinterferon alfa-2b) in combination with ribavirin was noninferior to Roche AG's Pegasys (peginterferon alfa-2a) - the standard of care - in treating patients with genotypes 2 and 3 chronic hepatitis C virus (HCV), with half as many injections. (BioWorld Today) Read More
